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ABSTRACT  
Objectives: This study aimed to measure lipoprotein (a) [Lp(a)], lipid profile and mean platelet volume (MPV) 
in hypothyroid patients compared to healthy controls.  
Methods: An unmatched case-control study was conducted involving 100 subjects (50 overt hypothyroidism 
patients and 50 healthy controls admitted to the University of Science and Technology Hospital, Al-Thawra Hos-
pital and Al-Jomhori Hospital- Sana'a, Yemen during the period from May 2013 to March 2014. Data were col-
lected by in-person interview using a structured questionnaire followed by weight and height measurements. 
Fresh blood samples were collected and analyzed using electrochemiluminescent, spectrophotometric and im-
munoturbidimetric methods for estimating Lp(a), lipid profile and MPV parameters. 
Results: Hypothyroid patients had a significantly higher concentration of Lp(a) compared to the control. Total 
cholesterol (TC), triglycerides and low-density lipoprotein-cholesterol (LDL-C) levels were also significantly 
higher in hypothyroid patients. Serum level of free triiodothyronine (FT3) was negatively correlated with Lp(a), 
TC and LDL-C (r=–0.380, p=0.007; r=–0.354, p=0.012; r=–0.350, p=0.013, respectively). However, serum thy-
roid-stimulating hormone was positively correlated with Lp(a), TC and LDL-C (r=0.344, p=0.015; r=0.299, 
p=0.035; r=0.405, p=0.004, respectively) among hypothyroid patients. MPV levels, on the other hand, showed a 
strong positive correlation with (r=0.611, p=0.001). 
Conclusions: These findings indicate that overt hypothyroidism patients tend to have increased Lp(a) and ath-
erogenic lipids that may contribute to increasing risk of atherosclerosis. However, hypothyroid patients showed 
no significant difference compared to the controls regarding the MPV 
Keywords: Hypothyroidism, Lipoprotein (a), Lipid profile, Mean platelet volume, Yemen 
  
© 2016 University of Science and Technology, Sana'a, Yemen. This article can be unrestrictedly used, distributed or reproduced 
in any medium, provided that credit is given to the authors and the journal.  
7 
Adlat et al., Yemeni J Med Sci 2016; 10:6–15. 
http://dx.doi.org/10.20428/YJMS.10.1.A1 
 
1. Introduction 
Thyroid disorders influence lipoprotein metabo-
lism (1–3). Changes in plasma cholesterol con-
centrations are primarily due to changes in the 
low-density lipoprotein (LDL) fraction. In hyper-
thyroidism, mRNA for LDL receptors is increased, 
leading to an increase in the number and activity 
of these receptors (2, 3), and therefore to a de-
crease in concentrations of LDL and total choles-
terol (TC) (2). However, inversed changes occur 
during hypothyroidism. The increase in apolipo-
protein B (apoB) and LDL concentrations is due 
to decreased removal rates rather than an in-
creased secretion (3). In addition, conflicting re-
sults have been reported with regard to lipopro-
tein (a) [Lp(a)] changes during thyroid dysfunc-
tion (4). 
Lp(a) was first identified as an LDL by Berg 
(5) in 1963, who succeeded in separating it into 
its lipid and protein components. The molecule 
consists of a lipid similar to that found in LDL and 
is the most complex and polymorphic of the lipo-
protein particles. It has been later found that 
apolipoprotein A (apoA) was linked to apoB100 
of LDL by disulfide linkages (4). The apoA struc-
tural gene is located on chromosome 6 with the 
gene for plasminogen, indicating that both might 
have arisen from a common ancestral gene (5, 6).  
It is noteworthy that Lp(a) is homologous to 
plasminogen, a protein causing the lysis of blood 
clots. Moreover, Lp(a) competes for the binding 
sites of plasminogen on the endothelium and may 
induce atherosclerosis by interfering with 
thrombolysis (7). In contrast to plasminogen, 
however, apoA cannot be converted to the prote-
olytic form. Therefore, Lp(a) can be expected to 
be a potentially thrombogenic and atherogenic 
agent. Because Lp(a) also shares the apoB anti-
gen with LDL, it may be metabolized through the 
LDL cholesterol (LDL-C) receptor pathway (8). 
The mean platelet volume (MPV) can reflect 
the platelet activity (9). Increased MPV has 
been associated with atherosclerotic lesions 
and cardiovascular diseases (CVD) (10, 11) as 
well as with diabetes, hypertension, dyslipid-
emia, smoking and obesity, which are CVD risk 
factors (12). Platelets play a critical role in 
thrombus formation and myocardial infarction 
after the rupture of an arteriosclerotic plaque 
in a coronary artery (10). Therefore, increased 
MPV may represent a risk factor for myocardial 
infarction. However, this is still controversial, 
where the majority of studies addressing the 
MPV role compared patients suffering from 
myocardial infarction with healthy controls 
(12). The available data regarding the relation-
ship between thyroid function and MPV are 
conflicting and limited to small-scale case-
control studies (18). The increased risk of ath-
erosclerosis and ischemic heart disease associ-
ated with hypothyroidism has been partially at-
tributed to dyslipidemia. Information on the ef-
fect of thyroid disorders on Lp(a) and MPV is 
limited and gives no final conclusion. It was re-
ported that hypothyroidism abnormalities do 
not lead to consistent changes in lipoproteins 
(15); however, some studies reported that hy-
pothyroidism affects the level of lipoproteins 
(16, 17). 
In the present case-control study, the asso-
ciation of overt hypothyroidism with Lp(a), li-
pid profile and MPV was examined by deter-
mining their serum levels. There is increasing 
evidence that increasing Lp(a), lipid profile and 
MPV play a pivotal role in developing coronary 
artery disease (18). Thyroid dysfunction alters 
the lipid profile through its effect on lipid me-
tabolism. Investigators have reported the effect 
of thyroid status on the changes in the serum 
lipoproteins, whereas reports on Lp(a) are lim-
ited, but the results remain controversial. 
Therefore, the aim of this study was to deter-
  
© 2016 University of Science and Technology, Sana'a, Yemen. This article can be unrestrictedly used, distributed or reproduced 
in any medium, provided that credit is given to the authors and the journal.  
8 
Adlat et al., Yemeni J Med Sci 2016; 10:6–15. 
http://dx.doi.org/10.20428/YJMS.10.1.A1 
 
mine Lp(a), lipid profile and MPV in patients 
with overt hypothyroidism compared to 
healthy controls. 
2. Methods 
2.1. Study design, subjects and ethical clear-
ance 
Fifty subjects with over hypothyroidism and 50 
apparently healthy controls were recruited in 
the present unmatched case-control study. The 
study was performed in the University of Sci-
ence and Technology Hospital, Al-Thawra Hos-
pital and Al-Jomhori Hospital- Sana'a, Yemen 
during the period from May 2013 to March 
2014. 
Patients aged between 18 and 65 years old 
with overt hypothyroidism detected on screen-
ing who agreed to participate were selected as 
cases. It was ensured that they had not taken 
anti-lipidemic drugs or oral contraceptives. In 
addition, patients with existing cardiovascular 
or renal diseases, type 2 diabetes mellitus or 
with a history of alcohol intake were excluded 
from the study. The control subjects were se-
lected from the hospitals excluding those who 
are coming from cardiology and diabetology 
departments to avoid possible confounders. 
The study protocol was approved by the Ethical 
Committee for Research on Human Subjects of 
the Faculty of Medicine and Health Sciences, 
Sana'a University. The purpose of the study was 
explained to all participants, and investigations 
were carried out after their written, informed 
consent. All subjects were categorized into two 
groups: Cases of overt hypothyroid subjects 
with thyroid-stimulating hormone (TSH) 5.0 
µIU/mL, free triiodothyronine (FT3) <1.45 
pg/mL and free thyroxin (FT4) <0.71 pg/dL 
and controls of healthy subjects with normal 
TSH, FT3 and FT4. 
Anthropometric parameters were evaluated 
as follows: weight was determined using elec-
tronic scales, height was measured with a stadi-
ometer, and body mass index (BMI) was calcu-
lated as weight in kilograms divided by the 
square of the height in meters. Approximately 
10 mL of venous blood were drawn from pa-
tients after 12-hour fasting. Blood samples were 
then immediately centrifuged at 2700 rpm for 
10 minutes at 4°C. Freshly separated serum was 
used for the determination of TSH, FT3 and FT4, 
while the remaining aliquots of serum were 
stored at –70°C until they were analyzed for 
Lp(a) and lipid profile. Blood samples were also 
collected into tripotassium EDTA-anticoagulated 
tubes for the measurement of MPV to avoid 
platelet swelling. 
2.2. Biochemical analyses 
Serum TSH, FT3 and FT4 were measured by 
electrochemiluminescence immunoassay using 
Elecsys autoanalyzer (Roche Diagnostics, Ger-
many). Serum TC, triglycerides (TG), high-
density lipoprotein-cholesterol (HDL-C) and 
Lp(a) were measured automatically using Cobas 
C501 analyzer (Roche Diagnostics, Germany). 
LDL levels were calculated according to the 
Friedwald formula (20), where LDL (mg/dL) = 
TC–(HDL+1/5 × TG).  
2.3. MPV measurement 
The MPV was measured by Sysmex XE-2100 Au-
tomated Hematology Analyzer (Sysmex XE-
2100, Buckinghamshire, United Kingdom). 
2.4. Statistical analysis 
The data were analyzed by the Statistical Pack-
ages for Social Sciences (SPSS) software version 
20.0 (IBM Inc., New York, USA). Continuous data 
were checked for normality of distribution by 
the Kolmogorov-Smirnov statistical test and the 
results were expressed as mean ± Standard de-
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viation (SD) or as median ± interquartile range 
(IQR). Student’s independent t-test or Mann-
Whitney U test, whichever suitable, was used to 
compare the continuous variables of the two 
groups. Categorical variables were analyzed 
with the chi-square or Fisher’s exact tests. Cor-
relation was measured using Spearman̕s rank 
correlation coefﬁcient (r). All p-values were 
two-sided, and a p-value <0.05 was considered 
statistically signiﬁcant. 
3. Results 
Table (1) shows the sociodemographic charac-
teristics of cases and controls. There was no 
significant difference between cases and con-
trols with regard to cigarettes smoking. How-
ever, there was a significant difference between 
patients with overt hypothyroidism and healthy 
controls regarding age (p=0.001) and BMI 
(p=0.002), whereas a borderline significance 
(p=0.045) was found between the two groups 
regarding the educational level. 
Table 1. General characteristics of the study and control groups* 
Variable  
Hypothyroid 
group 
n (%) 
Control 
group 
n (%) 
p-
value 
Median age (years) 
37 
(32~43) 
30 
(24~38) 
0.001 
Median BMI (kg/m2) 
24.8 
(23.9~26.6) 
22.4 
(20.8~25.7) 
0.002 
Sex   
  
Male 11 (22) 20 (40) 
0.083 
Female 39 (78) 30 (60) 
Marital status (%)    
Single 10 (20) 9 (18) 
0.657 Married 36 (72) 39 (78) 
Widow 4 (8) 2 (4) 
Cigarette smoking    
Never 44 (88) 43 (86) 
0.603 Past 0 (0) 1 (2) 
Current 6 (12) 6 (12) 
Educational level     
Illiterate 20 (40) 9 (18) 
0.045 
Basic education 12 (24) 10 (20) 
High school 8 (16) 10 (20) 
University and above 10 (20) 21 (4) 
*Number of cases and controls are 50 each; BMI; body mass index; (...~...), 
interquartile range  
Table (2) compares the laboratory findings 
of thyroid hormones, Lp(a), lipid profile and 
MPV among hypothyroid patients and healthy 
controls. Serum TSH was significantly (p=0.001) 
higher in the hypothyroid group by 33.6-fold, 
while FT3 and FT4 were significantly (p<0.001) 
lower in hypothyroid patients by 67.4 and 
65.8%, respectively, as compared to controls. 
The levels of TC, TG and LDL-C were significant-
ly higher by 1.12-, 1.7- and 1.2-fold, respectively, 
compared to controls, but there was no signifi-
cant difference in HDL-C levels between the two 
groups. Hypothyroid patients also had signifi-
cantly higher Lp(a) by about two-fold compared 
to controls, but there was no significant differ-
ence in MPV between the two groups. 
Table 2. Comparison of thyroid hormones, Lp(a), lipid profile and 
MPV between hypothyroid patients and controls in Sana'a, Yemen* 
Parameter 
Hypothyroid 
group 
Control 
group 
p-
value 
TSH (µIU/mL) 
56.1 
(23.3~95) 
1.67 
(1.26~2.62) 
0.001 
FT3 (pg/mL) 
1.05 
(1.0~1.31) 
3.23 
(2.9~3.70) 
0.001 
FT4 (pg/mL) 
0.41 
(0.30~0.60) 
1.20 
(1.31~1.32) 
0.001 
TC (mg/dL) 
217 
(201~260) 
192.5 
(169~220) 
0.001 
TG (mg/dL) 
188 
(115~237) 
116.5 
(103~159) 
0.001 
HDL-C (mg/dL) 45.1±8.42 43.2±8.56 0.256 
LDL-C (mg/dL) 
132 
(99~163) 
109.5 
(92~122) 
0.004 
Lp(a) (mg/dL) 
38.3 
(26.8~44.3) 
17.5 
(12~23) 
0.001 
MPV (fL) 10.7±1.18 10.9±1.15 0.568 
*Number of cases and controls are 50 each; TSH, thyroid-stimulating hor-
mone; FT3, Free triiodothyronine; FT4, free thyroxin; TC, total cholesterol; 
TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; Lp(a), lipoprotein (a); MPV, mean platelet 
volume; (... ~...), interquartile range  
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Table (3) shows the correlation of thyroid 
hormones with Lp(a), lipid profile and MPV in 
hypothyroid patients. Serum FT3 was negative-
ly correlated with Lp(a), TC and LDL-C (r=–
0.380, p=0.007; r=–0.354, p=0.012; r=–0.350, 
p=0.013, respectively). However, serum TSH 
was positively correlated with Lp(a), TC and 
LDL-C (r=0.344, p=0.015; r=0.299, p=0.035; 
r=0.405, p=0.004, respectively). On the other 
hand, FT4 was positively correlated with MPV 
(r=0.611, p=0.001). Table (4) shows that Lp(a) 
was positively correlated with TC and LDL-C 
(r=0.453, p=0.001; r=0.430, p=0.002, respec-
tively). 
Table 3. Correlation of thyroid hormones with biochemical pa-
rameters, MPV and BMI among hypothyroid patients in Sana'a, 
Yemen 
Variable 
TSH FT3 FT4 
r p-value r p-value r p-value 
TC 0.299 0.035 –0.354 0.012 –0.125 0.387 
TG 0.037 0.796 –0.045 0.757 0.208 0.146 
HDL-C 0.114 0.432 0.070 0.629 0.091 0.528 
LDL-C 0.405 0.004 –0.350 0.013 –0.051 0.726 
Lp(a) 0.344 0.015 –0.380 0.007 –0.231 0.106 
MPV 0.015 0.920 0.102 0.480 0.611 0.001 
BMI –0.152 0.292 0.223 0.119 0.269 0.059 
r, Spearman's correlation coefficient; TC, total cholesterol; TG, triglycer-
ides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipo-
protein cholesterol; Lp(a), lipoprotein (a); MPV, mean platelet volume; 
BMI; body mass index  
Table 4. Correlation of lipoprotein (a) with lipid profile among 
hypothyroid patients in Sana'a, Yemen 
 
TC TG HDL-C LDL-C 
r 
p-
value 
r 
p-
value 
r 
p-
value 
r 
p-
value 
Lp(a) 0.453 0.001 –0.006 0.966 0.012 0.932 0.430 0.002 
r, Spearman's correlation coefficient; TC, total cholesterol; TG, triglycer-
ides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipo-
protein cholesterol; Lp(a), lipoprotein (a)  
4. Discussion 
The significant increase in Lp(a) levels in hypo-
thyroid patients is in line with previous studies 
(16, 21). A cross-sectional study conducted in 
Seoul, Korea by Lee et al. (22) on 33 cases of 
overt hypothyroidism and 190 cases of subclini-
cal hypothyroidism showed non-significantly 
different Lp(a) levels among the two groups. 
The effect of thyroid hormones on Lp(a) is still 
controversial. These discrepant results may be 
attributed to genetic polymorphism of apoA 
(23), study design, collection and storage of 
samples, statistical analysis, and population dif-
ferences that reflect the known ethnic variability 
in the distribution of Lp(a) levels (24). Addition-
ally, the disagreement may also be related to the 
apoA size heterogeneity that greatly affects the 
accuracy of Lp(a) antibody-based analytical 
methods that recognize the variably repeating 
kringle IV type 2 (24). Moreover, the results of 
Lp(a) raise doubt about its role as an independ-
ent risk factor for CVD, suggesting its synergistic 
contribution to CVD by enhancing the effect of 
other lipid risk factors. It is evident that Lp(a) 
and LDL can act additively in the development of 
CVD (24). In addition, a high serum Lp(a) level 
can be a risk factor for coronary heart disease, 
atherosclerosis and thrombosis (21). 
The findings of the present study are in 
agreement with those obtained by Pop-Radu 
and Glig (21), who found a significant positive 
correlation between TSH and Lp(a) in hypothy-
roid patients in a randomized, descriptive case-
control study in Romania. However, the present 
findings disagree with those reported by Lee et 
al. (22), who found no correlation between 
Lp(a) and TSH or FT4 between hypothyroid pa-
tients and normal controls. This discrepancy 
may be due to polymorphisms in the apoA gene, 
which can cause considerable inter-individual 
variations in the production of Lp(a), or may be 
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due to the differences between the study 
groups. Furthermore, the effect of thyroid hor-
mones on Lp(a) may depend on the degree of 
thyroid failure (26). 
The findings of the present study are con-
sistent with that of Pop-Radu and Glig (21), 
who reported a significant negative correlation 
between FT3 and the levels of Lp(a), suggesting 
the influence of thyroid hormones on Lp(a) me-
tabolism. Because of the sequence homology of 
apoA with plasminogen, Lp(a) may compete for 
plasminogen by binding to its receptors, indi-
cating its link to thrombus formation and being 
an independent, genetically-determined risk 
factor for arteriosclerosis (23). In contrast to 
the finding of Pop-Radu and Glig (21), no signif-
icant correlation was found between FT4 and 
Lp(a) in the present study.  
In the present study, the MPV showed a 
non-significant difference between hypothyroid 
patients and normal controls. This finding is 
similar to that observed by Torun et al. (27), 
who found no significant difference in MPV lev-
els between overt hypothyroidism (10.2 fL) and 
subclinical hypothyroidism (9.4 fL) among non-
obese women patients of reproductive age in 
Sanliurfa, Turkey. On the other hand, some re-
searchers reported elevated MPV levels in hy-
pothyroid patients (18). Large platelets with in-
creased MPV values are active and release more 
thromboxane A2 than smaller ones, leading to 
an increased tendency to thrombosis (18). The 
absence of a significant difference in the MPV 
levels in the present study could be attributed 
to the different strategy of case selection. It is 
noteworthy that there is a limited number of 
contradictory reports in the literature that deal 
with this matter. Macey et al. (46) showed that 
the changes in MPV were greatest between 30 
and 60 minutes in blood stored at ambient 
temperature. However, blood samples were an-
alyzed within 5 minutes in the present study, 
considerably strengthening the accuracy of the 
present MPV results. 
Elevated MPV levels have been reported in 
subclinical hypothyroidism as a risk factor for 
cardiovascular complications. Van Doormaal et 
al. (14) demonstrated in a study conducted in 
the Netherlands that hypothyroidism leads to 
smaller platelets, whereas Ford and Carter (28) 
reported opposing results. The MPV cut-off val-
ue for predicting of future cardiovascular events 
is not clear (27). Some reports suggest values as 
high as 10.3 fL while others suggest 9 fL as an 
MPV cut-off value (29–31). 
In the present study, there was a significant 
positive correlation between FT4 and MPV in 
hypothyroid patients compared to controls, but 
no correlations were found with TSH and FT3. 
This is in agreement with a recent study by Atile 
et al. (32), who reported the absence of associa-
tion between MPV levels and TSH and FT3 in 
hypothyroid patients. Limited and conflicting 
data on the association between thyroid func-
tion and MPV have been reported in small-scale 
case-control studies (18). However, the poten-
tial usefulness of MPV as a prognostic marker 
for venous thromboembolism and various types 
of arterial thrombosis was concluded in a popu-
lation-based metanalysis, making it acceptable 
as a new risk factor for atherosclerosis (32). 
 
In the present study, the significant increas-
es in TC and LDL-C in hypothyroid patients are 
in line with those reported by Shashi et al. (16), 
Kaliaperumal et al. (33) and Regmi et al. (34). 
This increase may be attributed to the raised se-
rum LDL-C concentration (23), the effect of thy-
roid hormones on lipoprotein lipase activity that 
hydrolyzes the TG-rich lipoprotein (35) and the 
decreased activity of LDL receptors, leading to 
decreased catabolism of LDL and intermediate-
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density lipoprotein (IDL) (36). Furthermore, 
the promoter of the LDL receptor gene contains 
the thyroid hormone response element, which 
allows the FT3 to upregulate the gene expres-
sion of LDL receptors (23). These could con-
tribute to atherogenesis. Moreover, thyroid 
hormones induce the hepatic de novo choles-
terol synthesis by stimulating the enzyme 3–
hydroxy–3–methyl-glutaryl-CoA (HMG-CoA) 
reductase, which catalyzes the conversion of 
HMG-CoA to mevalonate leading to an in-
creased cholesterol synthesis in hyperthyroid-
ism and a decreased one in hypothyroidism 
(23). In addition, thyroid hormones control the 
expression of surface LDL-C receptors, affecting 
protein synthesis and lipoprotein metabolism 
(37). Hypothyroidism also increases total fatty 
acids, apoB–100 content of LDL and LDL oxida-
tion, and the increased cholesterol levels can be 
considered as a substrate for the oxidative 
stress, increasing the risk of atherosclerosis 
(23).  
The absence of correlation between TSH 
level and BMI in the present study is in contrast 
to that reported by Dipankar et al. (39), who 
found that TSH correlated positively with BMI 
in the hypothyroid compared to the lean group, 
considering BMI as a reliable indicator for the 
body adiposity assessment. Therefore, de-
creased thyroid hormones in hypothyroid pa-
tients may well explain the significant increase 
in BMI of these patients compared to controls. 
However, the effect of TSH on lipids is different 
in overweight and normal weight populations 
and between men and women. Serum TSH, sex 
and BMI have significant effects on serum lipid 
profile (40). The present study revealed a sig-
nificant positive correlation between TSH and 
TC, supporting the data reported by Risal et al. 
(17). This correlation indicates that lipid ab-
normalities can result from thyroid dys-
function (26). 
Serum HDL-C in the present study was non-
significantly lower in hypothyroid patients com-
pared to the controls, which is in agreement 
with previous studies (38, 39). However, this 
finding differs from other studies (41, 42), which 
reported a significant increase in serum HDL-C 
levels in hypothyroid patients. These conflicting 
results may be partly because of the reported 
regulation of cholesteryl ester transfer protein 
and hepatic lipase activity by thyroid hormone 
(23). 
The observed significant increase in TG in 
hypothyroid patients in the present study is sim-
ilar to that reported by Shashi (16), who found 
significantly increased TG levels in overt and 
subclinical hypothyroidism patients compared 
to normal controls in Punjab, India, and this 
could be explained by a reduced removal rate of 
TG from plasma and the accumulation of IDL 
(23). Hypertriglyceridemia is frequently associ-
ated with premature coronary artery disease 
(43, 44), which is defined by the occurrence of a 
myocardial infarction or the need for a coronary 
artery procedure (42).  
The findings of the present study are limited 
by the small sample size that might not detect 
the real diversity of MPV levels between hypo-
thyroid patients and controls and the lack of an 
accurate measurement method for Lp(a) that 
could affect the biochemical analysis due to the 
heterogeneity of apoA. In addition, the meas-
urement of Lp(a) in frozen sera is likely to result 
in a falsely lower Lp(a) concentrations.  
5. Conclusions 
Hypothyroid patients in Yemen may be at par-
ticular risk of atherosclerosis and CVD. There-
fore, screening for Lp(a) levels could be useful in 
patients with hypothyroidism to reduce the as-
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sociated disease. In addition, further studies 
with larger sample sizes are required to accu-
rately determine the alterations in Lp(a) and 
MPV levels as well as the actual risk for CVD in 
hypothyroid patients. 
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